The Changing Biotech Landscape – Challenges, Innovation, and Policy

The biotech industry has long thrived at the intersection of science, policy, and capital markets, but that intersection today seems more like a collision, with forces pushing against each other in ways that demand urgent attention. At our recent Russo Partners Advisory Board meeting, industry leaders convened to discuss the critical issues shaping biotech today—from diversity in clinical trials and regulatory ambiguity to capital market pressures and increasing global competition.

To help biotech companies navigate these growing complexities, we assembled an Advisory Board of industry veterans who have shaped biotech’s evolution for decades and continue to influence its trajectory. At this time of major transition, they offer critical insights and strategic counsel.

As I reflect on the dialogue, one thing is clear: Biotech leaders must rise and assume a more engaged role in shaping the future of our industry. While the challenges ahead are significant, we can shape the future of biotech with decisive action.

Clinical Trial Diversity: A Clinical Scientific and Industry Imperative

Enriching clinical trial populations with diversity isn’t just an ethical issue—it’s a scientific necessity. Yet, clinical trial diversity remains one of the biggest hurdles in drug development due to logistical barriers, patient trust issues, and regulatory uncertainty that continue to slow progress.

There was a strong voice in our board meeting that diversity in clinical trials must be unbundled from corporate DEI initiatives. While they are grouped, they require distinct solutions, investments, and separate commitments. “Drug companies are beginning to appreciate [diversity],” said one board member, “it’s good for drug development and the effectiveness of drugs when we’ve got a diverse population.”

Diversity or stratification involves:

• Partnering with trusted community health institutions to improve trial awareness, enhance accessibility, and reach diverse populations
• Expanding the use of digital technologies to enhance accessibility of decentralized trials, especially in underrepresented communities.
• Advocating for regulatory policies and funding that enable diversity initiatives.

The previous FDA administration took steps to formalize diversity requirements in clinical trials, signaling that inclusion was a regulatory expectation. However, the recent removal of draft guidance has created ambiguity, leaving biotech companies uncertain about how diversity expectations will be enforced moving forward. Most importantly, without broad representation in clinical trials, it becomes harder to determine the efficacy of treatment in different patient populations, reducing their credibility and potential impact.

Investment Trends: AI’s Role in Biotech and Global Trends

The biotech investment scene has dramatically shifted. IPOs remain scarce, venture capital is tightening, and most investors focus a disproportionate share of their portfolio into AI. “You cannot have a business plan without saying AI,” said one board member. “They often don’t know what it means.”

While AI investment in biotech is accelerating, an emerging fear is that firms hype AI’s potential to attract funding despite the lack of clear applications for the technology. Without meaningful progress, overreliance on AI could lead to future skepticism, reducing investor trust and capital flow.

Meanwhile, China’s biotech sector is expanding rapidly, competing directly with U.S. firms by disseminating their products here and attracting significant investment. Many of the largest pharma companies are now bypassing local venture-backed firms and instead partnering directly with Chinese biotechs.

As capital shifts and global competition intensifies, U.S. biotech firms must rethink their global strategies. This may involve exploring alternative funding models, forging strategic alliances, and leveraging AI effectively in research and development.

Regulatory Uncertainty: Navigating Evolving Policy in Biotech

Robert Kennedy, Jr.’s appointment as Health and Human Services Secretary has introduced new dynamics to the regulatory environment affecting the biotech industry. Notably, the unexpected cancellation of the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, originally scheduled for March 13, 2025, has raised concerns among healthcare professionals and industry stakeholders. This meeting is traditionally held to select influenza strains for the upcoming flu season, a process critical for timely vaccine production.

Kennedy’s vaccine skepticism and discussions about implementing stricter conflict-of-interest policies could create broader disruptions to biotech approvals—potentially slowing down authorizations across multiple therapeutic areas. His review of major vaccine contracts and consideration of policy changes signal a possible shift toward increased scrutiny in approval processes.

Beyond vaccine mandates, FDA leadership and talent could face further disruption if new policies mandate regulatory reviewers to work in-office full-time. Losing experienced reviewers would further strain an already cumbersome approval process, leading to delays that biotech companies can’t afford. In an industry where the pace of the market can determine success or failure, this change could be catastrophic.

While such uncertainties present difficulties, they also underscore the need for biotech leaders to participate in regulatory discussions. We cannot afford to be spectators. Instead, we must guide the conversation and advocate for a regulatory framework where safety and innovation coexist.

Biotech’s Future Direction

Biotech is being reshaped by diversity mandates, financial and global pressures, and regulatory shifts—challenges that demand proactive leadership. These challenges create opportunities for companies willing to take risks, innovate, and be changemakers in biotech.

In Part 2, I’ll explore the growing pressures on drug pricing, the uncertain future of public health funding, and the critical role biotech CEOs must play in shaping industry policy. As I continue this conversation on the forces shaping our industry, follow me for updates.